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Abstract
Through the Mectizan® Donation Program, Merck & Co., Inc. has donated Mectizan (ivermectin,
MSD) for the treatment of onchocerciasis worldwide since 1987. Mectizan has also been donated
for the elimination of lymphatic filariasis (LF) since 1998 in African countries and in Yemen where
onchocerciasis and LF are co-endemic; for LF elimination programs, Mectizan is co-administered
with albendazole, which is donated by GlaxoSmithKline. The Mectizan Donation Program works in
collaboration with the Mectizan Expert Committee/Albendazole Coordination, its scientific
advisory committee. In 2005, a total of 62,201,310 treatments of Mectizan for onchocerciasis were
approved for delivery via mass treatment programs in Africa, Latin America, and Yemen. Seventy-
seven percent and 20% of these treatments for onchocerciasis were for countries included in the
African Programme for Onchocerciasis Control (APOC) and the former-Onchocerciasis Control
Programme in West Africa (OCP), respectively. The remaining 3% of treatments approved were
for the six onchocerciasis endemic countries in Latin America, where mass treatment is carried out
twice-yearly with the goal of completely eliminating morbidity and eventually transmission of
infection, and for Yemen. All 33 onchocerciasis endemic countries where mass treatment with
Mectizan is indicated have ongoing mass treatment programs. In 2005, 42,052,583 treatments of
co-administered albendazole and Mectizan were approved for national Programs to Eliminate LF
(PELFs) in Africa and Yemen. There are ongoing PELFs using albendazole and Mectizan in nine
African countries and Yemen; these represent 35% of the total number of countries expected to
require the co-administration of these two chemotherapeutic agents for LF elimination. In Africa,
the expansion of existing PELFs and the initiation of new ones have been hampered by lack of
resources, technical difficulties with the mapping of LF endemicity, and the co-endemicity of LF and
loiasis. Included in this review are recommendations recently put forward for the co-administration
of albendazole and Mectizan in areas endemic for LF, loiasis, and onchocerciasis.
Review
Introduction
On the occasion of the 35th Mectizan® Expert Committee/
Albendazole Coordination meeting (MEC/AC35) which
took place in London, United Kingdom from 10–12 Jan-
uary 2006, a review of the work of the Mectizan Donation
Program (MDP) in onchocerciasis (river blindness) con-
trol and lymphatic filariasis (LF) elimination during 2005
was presented. Highlights from that review are summa-
rized below. The MDP is an international public health
organization supported by Merck & Co., Inc. to oversee
the donation of Mectizan (ivermectin, MSD) for
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onchocerciasis control worldwide and by Merck and Glax-
oSmithKline (GSK) to oversee their donations of Mecti-
zan and albendazole, respectively, for LF elimination in
the countries where the two diseases are co-endemic.
Background
In 1987, Merck announced the donation of Mectizan for
the treatment of onchocerciasis worldwide for as long as
necessary. The following year, Merck established the Mec-
tizan Expert Committee (MEC); the MEC is an independ-
ent, advisory committee of seven recognized experts in the
field of international public health and/or tropical medi-
cine charged with providing advice and guidance in devel-
oping policies and procedures to assure the safe, effective,
and appropriate use of Mectizan. Shortly thereafter, the
MDP was created to serve as the secretariat for the MEC
and to manage the day to day operations of the donation
[1].
In 1998, Merck expanded its donation of Mectizan for use
in national Programs to Eliminate LF (PELFs) in 28 Afri-
can countries and in Yemen where onchocerciasis and LF
are co-endemic [1]. When used in PELFs, a single dose of
Mectizan is co-administered with a single dose of alben-
dazole [2-4]. GSK has appointed two LF technical advisors
to work with the MEC in making technical and program-
matic decisions regarding the co-administration of Mecti-
zan with albendazole for LF; as a consequence, the
committee is now known as the Mectizan Expert Commit-
tee/Albendazole Coordination. The MEC and MEC/AC
have met on a regular basis since their respective incep-
tions.
Treatment indications and eligibility
Mectizan is indicated for the treatment of onchocerciasis
caused by Onchocerca volvulus and for the treatment of the
microfilaremia caused by infection with Wuchereria ban-
crofti, the causative agent of LF in Africa [5]. The oral dose
of Mectizan recommended for mass treatment programs
for the control of onchocerciasis or for the elimination of
LF is approximately 150–200 micrograms (µg)/kilogram
(kg) of bodyweight [3,4]. Each tablet of Mectizan contains
3 milligrams (mg) of ivermectin, and such tablets are
referred to as "3 mg tablets" [5]. The number of 3 mg tab-
lets needed to achieve the recommended dose is deter-
mined by an individual's bodyweight or height [5]. If
bodyweight is used as the dosing criteria, those weighing
less than 15 kg are ineligible for treatment; while if height
is used, those less than 90 centimeters tall are ineligible.
Others ineligible for treatment with Mectizan are preg-
nant women, women breast-feeding infants less than one
week old, individuals with serious illnesses of an acute or
chronic nature, and individuals with a history of hyper-
sensitivity response to Mectizan [4]. Using annual treat-
ment and Mectizan usage data from mass treatment
programs over the years, the MDP has calculated that the
typical number of 3 mg tablets used per person treated is
approximately three (average dose).
When used in PELFs, the recommended dose of Mectizan
(150–200 µg/kg bodyweight) is provided with a standard
dose of albendazole (one 400 mg tablet per person), and
the same ineligibility criteria used for Mectizan are
applied [3,4].
In this article, the expressions "approved treatments" and
"treatments approved" (and variations thereof) for
onchocerciasis correspond to the number of average doses
of Mectizan approved in a stated year and do not corre-
spond to the number of individuals to be treated since, in
several programs, individuals are treated more than one
time per year. When these expressions are used with
regard to PELFs, they correspond to the number of average
doses of Mectizan and standard doses of albendazole
approved in a stated year and do correspond to the
number of individuals to be treated since individuals are
treated only one time per year in PELFs.
Onchocerciasis overview
In 2005, the MEC approved 62,201,310 treatments with
Mectizan for onchocerciasis to be delivered via mass treat-
ment programs in endemic countries. An additional
31,200 treatments were approved via the Humanitarian
Donation Program (HDP) which serves the needs of phy-
sicians, clinics, and small organizations around the world
in need of Mectizan for the treatment of individuals with
onchocerciasis in areas where mass treatment is not being
implemented; these account for 0.05% of the overall treat-
ments approved (62.23 million) for onchocerciasis in
2005 (Figure 1).
Since 1988, when Merck made its first donations, enough
Mectizan has been provided for over 467 million treat-
ments for onchocerciasis for delivery via mass treatment
programs; if these treatments are combined with those
approved cumulatively through the HDP, the overall total
is over 470 million as of the end of 2005 (Figure 1). Mass
treatment with Mectizan for onchocerciasis is currently
ongoing in each of the 33 endemic countries where this
treatment strategy is justified by the particular epidemio-
logical situation (i.e. ≥ 40% positive skin snip prevalence,
≥ 20% onchocercal nodule prevalence in adult males ≥ 20
years of age, maintenance of previous control efforts, or as
a strategy for the interruption of transmission) [6-10]. Fig-
ures 2 and 3 illustrate the 26 countries in Africa and the
foci in the six endemic Latin American countries, respec-
tively, where mass treatment with Mectizan for onchocer-
ciasis is currently indicated and ongoing; the African
countries are color-coded to reflect their inclusion in the
former Onchocerciasis Control Programme in West AfricaFilaria Journal 2006, 5:11 http://www.filariajournal.com/content/5/1/11
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(OCP) or African Programme for Onchocerciasis Control
(APOC) regions. The 33rd country with ongoing mass
treatment with Mectizan for onchocerciasis is Yemen
which is not depicted in Figure 2 or 3.
Africa
APOC region
APOC is a regional program established in 1995 and exe-
cuted by the World Health Organization (WHO) with the
support of the World Bank and the private and public sec-
tors. Before 2010 when its operations are scheduled to
close, APOC will strive to support the establishment of
effective and self-sustainable, annual, community based
mass treatment with Mectizan in all onchocerciasis
endemic foci in countries in Africa in need of such inter-
vention and that were not included in the OCP [11,12].
APOC's ultimate goal is 'to eliminate onchocerciasis as a
disease of public-health importance and an important
constraint to socio-economic development throughout
Africa' [11].
The greatest proportion of treatments with Mectizan
approved by the MEC for delivery via mass treatment pro-
grams for onchocerciasis in 2005 (77.4%) was for coun-
tries in the APOC region (Figures 2 and 4). Among the
approvals in the region were treatments with Mectizan for
a new program in the Extreme North Province, Cameroon
and for the re-launching of two programs, in the Bururi
and Rutana foci in Burundi, each having had a period of
interruption due to civil unrest.
Former-OCP region
The countries in the former-OCP region began incorporat-
ing treatment with Mectizan into OCP activities, namely
vector control, shortly after the announcement of the
donation was made [7,13]. The drug was first distributed
where onchocercal blindness was most prevalent in the
program area [7,13]. Its use was later expanded to comple-
ment the program's ongoing larviciding activities and into
program areas where larviciding was not epidemiologi-
cally justified or cost-effective but control measures were
Treatments with Mectizan Approved for Onchocerciasis, 1988–2005 (Humanitarian Donation and Mass Treatment Programs  Combined) Figure 1
Treatments with Mectizan Approved for Onchocerciasis, 1988–2005 (Humanitarian Donation and Mass Treat-
ment Programs Combined). The figure in the 2005 column refers to the total number of treatments with Mectizan 
approved (rounded to the nearest 10,000) during the 2005 calendar year for onchocerciasis for mass treatment programs and 
humanitarian donations combined. For any given year indicated in this figure, the year of treatment approval may be different 
from the year during which treatments actually occurred.
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indicated [7,13]. In 1991, eleven years prior to the formal
closure of the OCP, its Devolution Unit began the process
of transferring the full responsibility for onchocerciasis
control and surveillance activities to the ministries of
health of each of the 11 member countries where that
responsibility remains today [13].
Mass distribution of Mectizan for onchocerciasis is cur-
rently indicated in foci in all of the former-OCP countries,
with the exception of Niger, for the purpose of maintain-
ing the OCP's accomplishments (Figure 2) [7-9,13,14].
Moreover, in recent years, mass treatment with Mectizan
for onchocerciasis has been extended into forested regions
of some former-OCP countries; such regions were not
included in the OCP's operations because blinding
onchocerciasis (OCP's priority) was less prevalent. In
Niger, where the numbers of individuals at risk for
onchocerciasis are too few to justify mass treatment, clinic
based treatment is provided for those infected. Treatment
with Mectizan was approved in 2005 for the re-launching
of mass treatment of onchocerciasis in Guinea-Bissau
which will be integrated with the country's newly estab-
lished, national PELF.
Intensified control efforts have been instituted in the
"Special Intervention Zones" (SIZ) where, for various rea-
sons, there were unsatisfactory program results at the end
of 2002 when the OCP formally closed [9]. The SIZ
include the basins of the Pru river in Ghana, the tributar-
ies of the Oti and Upper Oueme rivers in Togo/Benin, the
Mafou/Upper Niger and Tinkisso river basins in Guinea-
Conakry, and the entirety of Sierra Leone; the latter being
included due to the interruption of control activities dur-
ing the period of civil unrest in the 1990s and early 2000s
[9]. The goal of operations in the SIZ is to bring epidemi-
ological and entomological parameters to an acceptable
level [9]. Annual Mectizan treatment with high coverage
(85% of the total population) is recommended for all eli-
gible communities within the SIZ, with the communities
Foci in Latin America (OEPA region) where Onchocerciasis  is Endemic and where Mass Treatment with Mectizan is Indi- cated and Ongoing, as of the end of 2005 Figure 3
Foci in Latin America (OEPA region) where 
Onchocerciasis is Endemic and where Mass Treat-
ment with Mectizan is Indicated and Ongoing, as of 
the end of 2005. In Latin America (OEPA region), as of the 
end of 2005, all onchocerciasis endemic foci were indicated 
for twice-yearly mass treatment with Mectizan, regardless of 
endemicity, as a strategy for the elimination of onchocercal 
morbidity and transmission of infection. This map is repro-
duced with permission of the Annals of Tropical Medicine and 
Parasitology, 2006, Volume 100, pages 733–46.
The 26 Countries in Africa where Mass Treatment with Mec- tizan is Indicated and Ongoing for Onchocerciasis, as of the  end of 2005 Figure 2
The 26 Countries in Africa where Mass Treatment 
with Mectizan is Indicated and Ongoing for 
Onchocerciasis, as of the end of 2005. Countries are 
colored coded according to their inclusion in the former-
OCP ( ) or APOC ( ) regions. As of the end of 2005, 
there were mass treatment programs with Mectizan for 
onchocerciasis in all 26 African countries where such inter-
vention is epidemiologically justified. These 26 countries, plus 
Niger and Mozambique, are eligible for Mectizan combined 
with albendazole for national PELFs. This map is reproduced 
with permission of the Annals of Tropical Medicine and Parasi-
tology, 2006, Volume 100, pages 733–46.Filaria Journal 2006, 5:11 http://www.filariajournal.com/content/5/1/11
Page 5 of 11
(page number not for citation purposes)
in the Oti, Mafou, and Tinkisso basins receiving a second
round of treatment each year and aerial larviciding occur-
ring in the Oti and Oueme river basins [7,9,15]. In addi-
tion, twice-yearly treatment with Mectizan also occurs in
selected onchocerciasis endemic foci in Burkina Faso and
Senegal [7].
Twenty percent of the treatments with Mectizan approved
by the MEC for delivery via mass treatment programs for
onchocerciasis in 2005 were for countries in the former-
OCP region; this is sufficient Mectizan for 12.4 million
treatments (Figures 2 and 4). Mass treatment with Mecti-
zan at the same magnitude is projected for this region for
the foreseeable future or at least until there is evidence
that treatment can cease without the risk of disease recru-
descence [8,9,13,14]. A United Nations Development
Program/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases (TDR) spon-
sored study is underway in five foci in the former-OCP
region where the prevalence of onchocerciasis is currently
very low to determine if local elimination of transmission
has occurred and if, consequently, mass treatment with
Mectizan can be stopped [16].
Latin America-OEPA region
The Onchocerciasis Elimination Program for the Americas
(OEPA) is a multi-national and multi-agency coalition
established in 1993 that has the goal of completely elimi-
nating ocular morbidity attributable to onchocerciasis
and transmission of infection in the 13 endemic foci
found in six countries in Latin America (Figure 3) [10,17].
It is estimated that just over 500,000 people are at risk of
infection with O. volvulus in the region [18]. OEPA's strat-
egy is the twice-yearly treatment with Mectizan of individ-
uals in all onchocerciasis endemic communities in the 13
foci, regardless of the community's endemicity. As part of
the strategy, in each treatment round, national programs
strive to treat at least 85% of the population eligible for
Treatments with Mectizan Approved for Onchocerciasis (Mass Treatment Programs Only) by Region, 2005 Figure 4
Treatments with Mectizan Approved for Onchocerciasis (Mass Treatment Programs Only) by Region, 2005. 
The figure on top of each bar refers to the number of treatments (in millions) with Mectizan approved for delivery via mass 
treatment programs for onchocerciasis for the particular region or country indicated. All treatment approval figures have been 
rounded to the nearest 100,000, with the exception of that for Yemen (rounded to the nearest 10,000). The year of treatment 
approval may be different from the year during which treatments actually occurred.
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treatment with Mectizan in each endemic focus as that
should lead to interruption of transmission in the Latin
American setting [10,18].
As of 2005, the population eligible for treatment with
Mectizan for onchocerciasis in the region's 13 foci com-
bined was approximately 454,000 people [10]. For the
last three years (2003–2005), in all foci in the region, with
the exception of the southern focus of Venezuela, greater
than 85% of the eligible population have been treated
[10]. In 2005, the MEC approved 1,547,006 treatments
with Mectizan for onchocerciasis for the region, 2.5% of
the total treatments approved for delivery via mass treat-
ment programs for the year (Figure 4). For logistical rea-
sons, in 2005 national programs in the region were
offered the option of receiving sufficient Mectizan for two
years of treatment, rather than the standard practice of
annual supply; thus, the total treatments approved for the
year exceed the region's annual treatment objective of
approximately one million treatments (total eligible pop-
ulation X 2 cycles of treatment).
Epidemiological and entomological data on O. volvulus
and Simulium species and opthalmological examinations
in the region indicate that in selected foci in Colombia,
Ecuador, Guatemala, and Mexico transmission of infec-
tion may have already been interrupted [10,18]. The pos-
sibility that transmission has already been interrupted in
several foci and the virtual elimination of new cases of
blindness due to onchocerciasis in the region have led
OEPA to contemplate: i) the possible focal cessation of
mass treatment with Mectizan, ii) the process for docu-
mentation of the elimination of O. volvulus transmission,
and iii) the post-treatment surveillance that will be
needed [10, personal communication M. Sauerbrey]. The
region is currently reviewing the criteria for the certifica-
tion of interruption of transmission of human onchocer-
ciasis put forth by WHO, after a meeting of experts in
Treatments with Albendazole and Mectizan Approved for Programs to Eliminate Lymphatic Filariasis (PELFs), 2000–2005 Figure 5
Treatments with Albendazole and Mectizan Approved for Programs to Eliminate Lymphatic Filariasis 
(PELFs), 2000–2005. The figure on the top of each bar refers to the number of treatments (in millions) with albendazole and 
Mectizan approved for national PELFs in Africa and Yemen in the calendar year indicated. All annual treatment approval figures 
have been rounded to the nearest 100,000. For any given year indicated in this figure, the year of treatment approval may be 
different from the year during which treatments actually occurred.
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2001, to determine how they should be applied to the
Latin American setting [19].
Yemen
Onchocerciasis in Yemen has been described as occurring
in villages near main wadis (i.e. seasonal watercourses)
with permanent, westward flowing streams and some
associated tributaries, at altitudes between 300 and 1200
meters [20]. Available data indicate that the southern and
northern limits of onchocerciasis distribution are Wadi
Ghail in the southwest and Wadi Surdud in the northwest,
respectively [20]. Approximately 30,000 people are esti-
mated to be infected with O. volvulus in the country [21].
A particular dermal manifestation of onchocerciasis,
known as sowda, is commonly observed in Yemen. In
those with sowda, a single limb (often a leg) is typically
affected with severe pruritis, moderate edema, pachyder-
mia, papular or pustular eruption, and darkening of skin
color [20]. In addition, enlargement of femoral lymph
nodes can be seen [20]. Mectizan has been recommended
for use at 3-monthly intervals to control the clinical symp-
toms of sowda, and this strategy has since been adopted
in Yemen [22]. The distribution of Mectizan for onchocer-
ciasis in Yemen is primarily passive whereby those who
want treatment to relieve symptoms present to drug dis-
tributors. In areas where onchocerciasis is co-endemic
with LF, one annual cycle of co-administered Mectizan
and albendazole is provided through Yemen's national
PELF whereby all eligible community members in the pro-
gram area are included in treatment regardless of their
individual onchocerciasis or LF infection status; the addi-
tional quarterly treatments with Mectizan for sowda in
these co-endemic areas are provided passively to patients
who seek them. In 2005, the MEC approved 91,000 total
treatments with Mectizan, to be provided on a quarterly
basis, for onchocerciasis in Yemen; this represents 0.2% of
the total treatments approved for the year for onchocercia-
sis for delivery via mass treatment programs (Figure 4).
Humanitarian Donation Program
The HDP provides Mectizan to health care professionals
treating relatively small numbers of confirmed cases of
onchocerciasis in hospitals and clinics worldwide and has
been in existence since the donation was announced. In
the first years of the donation, the HDP was an important
mechanism through which Mectizan could be obtained
for patients with onchocerciasis; now, more than 99% of
the Mectizan needed is provided through national
onchocerciasis control programs (NOCPs) where the vast
majority of it is delivered via community based mass dis-
tribution and the rest via clinic based treatment. In 2005,
as much as possible, requests made to the HDP from
endemic countries with established NOCPs were for-
warded to national coordinators for review and supply; in
this way, all onchocerciasis control activities within an
endemic country can be coordinated at a central level. The
largest single donation made by the HDP in 2005 was
Mectizan for onchocerciasis for 10,000 displaced Suda-
nese living in refugee camps in Kenya, a country where
onchocerciasis is no longer endemic [23]. Other, smaller
donations were made for the treatment of individuals
with onchocerciasis in Central America, Europe, and the
Middle East.
Lymphatic Filariasis overview
Following a resolution by the World Health Assembly in
1997 to eliminate LF as a public health problem, the Glo-
bal Programme to Eliminate Lymphatic Filariasis (GPELF)
was launched by the WHO [2]. The recommended mass
drug administration (MDA) strategy for PELFs in coun-
tries co-endemic for onchocerciasis is a standard dose of
Mectizan (150–200 µg/kg bodyweight) co-administered
with a standard dose of albendazole (one 400 mg tablet
per person) on an annual basis for four to six years [3];
this strategy is applicable to 28 countries in sub-Saharan
Africa and to Yemen (Figure 2). Diethylcarbamazine
(DEC), used in PELFs in other countries with or without
albendazole, is not recommended for the above-men-
tioned 29 countries since it can induce serious adverse
events (SAEs) in individuals infected with O. volvulus and/
or Loa loa [3,24].
An added complication in LF elimination strategies for
Africa is the safety of the recommended chemotherapeutic
drugs in loiasis-endemic areas [25-27]. Clinical and epide-
miological data from Cameroon have demonstrated that
individuals with L. loa microfilaremia of > 30,000 micro-
filariae/milliliter blood are at risk, albeit rarely, of devel-
oping neurological SAEs after treatment with Mectizan
[28,29]. A positive linear relationship has been reported
between the average intensity and the prevalence of L. loa
infection in communities; thus community-level assess-
ments which estimate the prevalence of infection with L.
loa can be used to identify geographic areas where L. loa-
associated SAEs following treatment with Mectizan are
more likely to occur [30]. A spatial model of L. loa preva-
lence across west and central Africa has been developed
and linked to a geographical information system to create
a map that has been useful in identifying large geographic
areas where the risk of SAEs could be high [31]. The map
is instrumental for locating areas appropriate for further
evaluation with the Rapid Assessment Procedure for Loia-
sis (RAPLOA), a rapid assessment tool for the presence
and intensity of L. loa infection at the community level
[32]. In L. loa endemic areas, mass treatment with Mecti-
zan for onchocerciasis is carried out where the benefit of
treatment is deemed to outweigh the risk of L. loa-associ-
ated SAEs (i.e. where the prevalence of onchocerciasis is ≥
20% as measured by palpable onchocercal nodules or ≥
40% as measured by skin snips) [33,34].Filaria Journal 2006, 5:11 http://www.filariajournal.com/content/5/1/11
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Where mass treatment for onchocerciasis occurs in L. loa
endemic areas, it is implemented following the MEC/
Technical Consultative Committee (TCC) guidelines for
the treatment of onchocerciasis with Mectizan in areas co-
endemic for loiasis [34]. The TCC is APOC's scientific
advisory committee. In brief, the guidelines call for
enhanced education of community members, specialized
training for community volunteers and health personnel
in enhanced post-treatment surveillance, referral, prompt
and appropriate clinical management, and provision of
designated referral centers with appropriate medical sup-
plies in order to reduce the risk of neurological complica-
tions and death. Moreover, there are L. loa Technical
Advisors posted in the countries where the most L. loa-
associated SAEs have been reported; these advisors are
financially supported by MDP and APOC and provide L.
loa-related technical and clinical advice and assistance to
their respective NOCPs.
There have been no data published to date indicating that
Mectizan alone, or in combination with albendazole, pro-
vides a clinical benefit to individuals with W. bancrofti
infection. Thus at the present time, the use of these drugs,
in combination, in national PELFs in Africa and Yemen is
for the elimination of LF transmission through successive
reductions in microfilaremia with each annual treatment
round [3,24,35-37]. With this strategy, the benefit accrues
over time to the community but not immediately to an
infected individual. As a consequence, there has been a
reluctance to expand PELFs into areas co-endemic for LF
and loiasis where there would be a risk of L. loa-associated
SAEs and no documented clinical benefit to individuals
with LF [25-27]. In contrast, in L. loa endemic areas where
mass treatment with Mectizan for onchocerciasis is indi-
cated and thus the benefit of treatment outweighs the risk
of SAEs, the concern with initiating PELFs has been the
addition of albendazole into ongoing mass treatment
with Mectizan [38].
MDA for lymphatic filariasis in non-loiasis endemic areas
Between 2000 when the PELFs in Africa began and 2005,
approximately 120 million treatments of co-administered
albendazole and Mectizan were approved by the MEC/AC
for nine African countries and Yemen for MDA for LF
elimination (Figure 5). The nine African countries are
Benin, Burkina Faso, Ghana, Guinea-Bissau, Mali,
Nigeria, Tanzania, Togo, and Uganda. These 10 countries
with active PELFs represent 35% of the total number of
countries expected to require the co-administration of
albendazole and Mectizan for LF elimination. Of note,
both Benin and Nigeria have areas with L. loa endemicity;
the treatments approved by the MEC/AC for LF elimina-
tion in these countries have excluded such areas.
In 2005, 42,052,583 treatments of co-administered alben-
dazole and Mectizan were approved for PELFs in Africa
and Yemen; this figure is 13% of the ultimate annual treat-
ment goal projected (approximately 320 million annual
treatments) when all countries eligible to receive these
two drugs for PELFs in Africa and Yemen are combined
(Figures 2 and 5). In Africa, the expansion of existing
PELFs and the initiation of new ones have been slower
than anticipated primarily due to scarce human and
financial resources for field operations, technical difficul-
ties with the tools for endemicity mapping, and the co-
endemicity of loiasis and LF in many LF endemic coun-
tries [26,27,39]. As of the end of 2005, only two countries,
Togo and Yemen, had scaled up MDA sufficiently to reach
100% geographic coverage, and this occurred after at least
three rounds of treatment. Since the recommendation for
the duration of PELF MDA is four to six years, a slow rate
of scaling up translates into national PELFs of longer dura-
tion and possibly loss of political and societal momentum
for the program in addition to a decrease in overall effi-
ciency [3,27].
MDA for lymphatic filariasis in loiasis-endemic areas
As described above, there has been concern about launch-
ing PELFs in African countries known to be, or suspected
of being, endemic for L. loa [25-27]. However, progress
has recently been made in clarifying the safety issues of
conducting LF MDAs in loiasis-endemic areas. In 2005, an
informal consultation of experts, sponsored by WHO/
TDR, determined that there is neither a biological ration-
ale nor available data to suggest that the addition of
albendazole to Mectizan would increase the number or
severity of adverse reactions if the two drugs were to be
used together to treat populations co-endemic for
onchocerciasis, LF, and loiasis [38]. In addition, the
experts concluded that the most effective approach to
addressing the safety of this drug combination in areas
with triple endemicity is to use the drugs on a large scale
with intensified pharmacovigilance. One of the most sig-
nificant developments for LF elimination in Africa was the
recent endorsement, by all of MDP's partners during
MEC/AC35, of the conclusions made during the informal
consultation.
All partners agreed that in view of the well recognized
inverse relationship between the number of cycles of Mec-
tizan treatment and the incidence of SAEs seen in popula-
tions with any of these filarial infections, the specifics of
the enhanced pharmacovigilance required need not be the
same for all loiasis/LF/onchocerciasis co-endemic, or
potentially co-endemic, areas [38]. The following guide-
lines have thus been recommended for the initiation of
PELFs in L. loa endemic areas where mass treatment with
Mectizan for onchocerciasis is indicated:Filaria Journal 2006, 5:11 http://www.filariajournal.com/content/5/1/11
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• In those areas that have already received two or more
cycles of mass treatment with Mectizan for onchocerciasis
with good coverage (i.e. ≥ 65% therapeutic coverage of the
total population or ≥ 80% therapeutic coverage of the eli-
gible population), the level of L. loa microfilaremia in
individuals is likely to be reduced far below levels associ-
ated with encephalopathy and other SAEs. Consequently,
it can be recommended that the addition of albendazole
could proceed with enhanced passive surveillance as cur-
rently recommended in the above-mentioned MEC/TCC
guidelines for the treatment of onchocerciasis with Mecti-
zan in areas co-endemic for loiasis [34].
• In areas that have received no previous mass treatment
with Mectizan for onchocerciasis, one round of prior mass
treatment, or have had poor prior mass treatment cover-
age, active surveillance similar to that employed at the ini-
tiation of the GPELF should be undertaken until a
minimum of 15,000 individuals has been assessed [40].
This active surveillance should be undertaken only in
those areas where all of the medical safety mechanisms for
handling potential SAEs are well in place, as outlined in
the MEC/TCC guidelines for treatment in L. loa endemic
areas [34]. Based on the prior data from Cameroon, statis-
tical considerations indicate that assessment of 15,000
treated individuals would permit the detection of any sig-
nificant increase in SAEs that might be associated with the
addition of albendazole to Mectizan in such L. loa
endemic areas [41]. If no increase is seen during this active
surveillance, enhanced passive surveillance could then be insti-
tuted.
It should be noted that this recommendation does not
apply to areas where LF and loiasis endemicity overlap
with areas where mass treatment with Mectizan for
onchocerciasis is not indicated or where onchocerciasis is
not endemic; alternative strategies for LF elimination will
have to be considered in these areas.
Outlook for 2006
Onchocerciasis
Among the new mass treatment programs with Mectizan
for onchocerciasis to be launched in 2006 are one in the
Rutshuru-Goma focus located in North Kivu Province,
Democratic Republic of the Congo (DRC) and another in
the Littoral I focus in Littoral Province, Cameroon, an area
where the MEC/TCC guidelines for the treatment of
onchocerciasis with Mectizan in areas co-endemic for
onchocerciasis and loiasis will be implemented [34]. In
2006/2007, the MEC expects to receive new requests for
Mectizan for endemic foci in Angola, DRC, and Uganda
for the last remaining mass treatment programs with Mec-
tizan for onchocerciasis to be launched in Africa. Once
these programs are ongoing, all of the geographic areas
eligible for mass treatment for onchocerciasis worldwide
will be receiving Mectizan on an annual basis. Projections
indicate that, by 2010, there will be over 100 million peo-
ple receiving annual treatment with Mectizan for
onchocerciasis in endemic countries, with more than 86
million of these being in the APOC region [personal com-
munication L. Yameogo]. In light of this projection, con-
sideration is being given to extending APOC operations
beyond 2010 to assure sufficient time for all member
countries to establish sustainable mass treatment pro-
grams with Mectizan for onchocerciasis [42].
Lymphatic Filariasis
In 2006, the PELFs in Burkina Faso and Ghana plan to
join the ranks of those PELFs reaching 100% geographic
coverage of districts where the co-administration of alben-
dazole and Mectizan is indicated. Moreover, it is likely
that a PELF in Sierra Leone will be initiated this year which
is integrated with the existing onchocerciasis control pro-
gram.
Integrated control programs
In several countries in Africa (e.g. Benin, Burkina Faso,
Ghana, and Mali among others), national onchocerciasis
control activities and national PELFs have been integrated
since their intervention strategies are so similar. Other
examples of integration are regions in Cameroon, DRC,
Nigeria, and Uganda where Vitamin A is distributed dur-
ing mass treatment with Mectizan for onchocerciasis
[43,44]. In addition, in two states in Nigeria, MDA for
onchocerciasis and schistosomiasis control are integrated
with the LF elimination efforts. Uganda's PELF has
recently been integrated into Child Days Plus which as
part of its strategy includes deworming and immunization
campaigns. It is expected that, in 2006 and onward, addi-
tional countries will initiate and intensify efforts to inte-
grate onchocerciasis control with PELFs and with other
disease control activities [45,46].
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